Business Wire

NEXI-S.P.A

7.3.2024 07:31:27 CET | Business Wire | Press release

Share
Group Financial Results as of December 31st 2023 Approved, Strong Margin Expansion and Excess Cash Generation at € 601 Million, € 500 Million Share Buy-Back Program

The Board of Directors of Nexi S.p.A. approved on March 6th the Group’s consolidated financial results as of December 31st 2023.

"In 2023, we have continued our growth journey across all geographies, we have further increased our margins, and significantly accelerated cash generation. Additionally, we have made further progress in product innovation, in the modernization of our technological platforms, in the strengthening of our skills, and in the integration of our organization, which allows us to further accelerate efficiency and synergies," commented Paolo Bertoluzzo, CEO of Nexi Group. "Looking ahead, despite a still uncertain macroeconomic outlook, we expect to continue to expand our margins and significantly increase the cash generation, returning to accelerate revenues in the medium term, also thanks to new drivers of growth such as eCommerce, Germany, and Spain, which we recently acquired. Given this outlook, we are entering a new phase in terms of capital allocation: we have decided to initiate the process of returning capital to our shareholders, while continuing the ongoing reduction of financial leverage and sustaining the investments in the organic development of the business. For this reason, we will propose to the Shareholders' General Meeting to start a significant buy-back program, with the conviction that this is the most effective way to create value for our shareholders in this phase. This progress is possible thanks to the continued trust of our Customers, the support of our Partners, and the extraordinary contribution of the People of Nexi."

Key consolidated financial managerial results1

In FY23 the Group delivered revenues at € 3,361.7 million, +7.0% versus FY22, and EBITDA at € 1,751.8 million, +10.0% versus FY22. The EBITDA margin was at 52%, up by 146 basis points compared to FY22, also thanks to the accelerating efficiencies and synergies delivery on the back of Group integration.

4Q23 revenues reached € 912.9 million, +6.8% versus 4Q22. 4Q23 EBITDA was at € 484.1 million, +9.7% versus 4Q22, with EBITDA margin at 53%, up by 139 basis points compared to 4Q22.

Nexi Group’s operating businesses delivered the following results in FY23:

  • Merchant Solutions, representing approximately 56% of Group's total revenues, reported revenues of € 1,888.6 million, +7.7% Y/Y, with Germany and eCommerce growing double-digit. In FY23, 18,524 million transactions were processed, +12.6% Y/Y, with value of processed transactions at € 825.3 billion, +7.6% Y/Y. In FY23 transactions value growth continued across the Group, primarily driven by international schemes. In 4Q23, Merchant Solutions revenues reached € 497.9 million, +6.2% Y/Y.

    Acquiring volumes2 in 4Q23 increased mid-single digit Y/Y in Italy and the Nordics, while in the DACH region they recorded a strong double-digit Y/Y growth. In January and February, acquiring volumes continued their solid Y/Y growth across geographies, despite the overall macro weakness.

    The main initiatives realized in Merchant Solutions during 4Q23 include:
  • Extension of Group SME propositions across countries, including the SmartPOS being launched in the Nordics and SmartPay extension accelerating in new markets;
  • New strategic premium partnership at group level with WooCommerce, on top of the already signed similar advanced partnerships with key European e-commerce enablers (i.e., Magento, Shopware and Prestashop);
  • Extension of Group LAKA vertical propositions: solid pipeline of new customers wins and up/cross selling across multiple geographies and verticals (e.g. omni-channel retail, hospitality, EV charging/petrol).
  • Issuing Solutions, representing approximately 32% of Group's total revenues, reported revenues of € 1,090.1 million in FY23, +7.6% Y/Y, and € 300.8 million in 4Q23, +9.5% Y/Y. The growth was mainly supported by the success of international debit in Italy and by the already expected non-recurring contribution related to banks’ M&A, phasing and projects in Italy. In FY23, 19,290 million transactions were processed, +10.8% Y/Y, with value of processed transactions at € 888.0 billion, +8.2% Y/Y.
  • Digital Banking Solutions, representing approximately 11% of Group's total revenues, reported revenues of € 383.0 million, +1.8% Y/Y.

In 4Q23, Digital Banking Solutions reached € 114.3 million of revenues, +2.9% Y/Y, sustained by volume growth and new initiatives.

In FY23, Total Costs were at € 1,609.9 million, with a limited growth of 3.8% Y/Y despite volume growth and inflationary pressure, mainly due to the operating leverage and to the several synergies and efficiencies, on the back of Group integration. In 4Q23 Total Costs were at € 428.8 million, +3.7% versus 4Q22.

Total Capex3 were at € 496 million in FY23, equal to 15% net revenues, decreasing from € 520 million in FY22, down 4.6 p.p. Y/Y. In particular, € 386 million were related to the ordinary innovation of products and services, maintenance of high-quality services and security, POS and ATM purchase, and € 110 million were related to transformation and integration initiatives, with a small portion left to be completed in 2024.

Continued strong reduction of transformation and integration costs at € 116.1 million in FY23, down 24% versus FY22. Non-recurring items below EBITDA Reported (shown in the Annex) at € 1,458.3 million in FY23 and are affected by the technical non-cash impairment charge to the carrying value of goodwill and intangibles of € 1,256.8 million, reflecting the share price evolution and the current markets conditions.

Normalised net profit4 in FY23 was € 711.8 million, with normalised EPS at 0.54 € up by 4.9% Y/Y. The reported Group loss for FY23 Reported (shown in the Annex) is equal to € 1,006.0 million, following the above mentioned technical non cash impairment.

The excess cash generation5 was equal to € 601.16 million in FY23, confirming a strong growth.

As of December 31st 2023, the Net Financial Debt was down to € 5,262 million, while the Net Financial Debt / EBITDA ratio decreased at 3.0x, down -0.3x vs FY22. The weighted average debt maturity is ~3.1 years with an average pre-tax cash cost of debt, broadly stable versus 3Q23, of ~2.86%.

Share buy-back

The substantial existing cash balances and the strong current and expected cash generation growth allow to start returning capital to Shareholders in 2024, while still continuing to support the planned debt reduction and the limited M&A opportunities in the future.

Nexi’s management and the Board believe that the current share price does not reflect the full value of our business and its outlook and that a share buy-back offers the most effective value creating opportunity for the shareholders to deploy the excess cash.

Therefore, Nexi’s Board has resolved to propose an 18 months share buy-back program up to 500 €M (equal to ~13% free float) at the next Shareholders' meeting on April 30th, 2024.

In the longer term, Nexi plans to continue to allocate a material portion of excess capital to shareholders either through further share buy-back programs or dividends depending on overall market conditions.

2024 Guidance

For 2024, considering the persistent complex macro outlook, Nexi announces the following targets:

  • Net revenues: Mid-single digit Y/Y growth;
  • EBITDA: Mid-to-high single digit Y/Y growth, with margin expansion of 100 bps+;
  • Excess cash generation: More than 700 €M;
  • Net leverage: decreasing to below 2.9x including announced M&A and share buy-back effects, (~2.6x on organic basis).

Updated medium-term outlook

Nexi, assuming the continued robust cash-to-digital payments conversion in the key geographies where the Group is present and a gradual macro recovery in the medium term, foresees:

  • Revenues gradually re-accelerating from mid-single digit Y/Y growth;
  • EBITDA margin continuously expanding by ~100 bps+ per year;
  • Continued strong organic cash generation growth, expected to reach ~1 €B in 2026;
  • Target leverage at ~2.0x-2.5x EBITDA by 2026 after further capital return to shareholders (~1.5x on organic basis).

ESG Progress

The continuous progress within the scope of ESG has been acknowledged with important international recognitions throughout 2023, highlighting Nexi’s commitment to be NetZero by 2040 across the entire Group and to apply the same standards to the entire value chain, as well as its responsible approach to business, grounded in risk mitigation and a culture of diversity and inclusion.

* * *

Pursuant to paragraph 2 of article 154 bis of the Consolidated Finance Act, the undersigned, Enrico Marchini, in his capacity as the manager in charge of preparing Nexi’s financial reports, declares that the accounting information contained in this press release corresponds to the accounting documents, books and records of Nexi S.p.A..

Reported results under review by PricewaterhouseCoopers.

* * *

Disclaimer: This is the English translation of the original Italian press release “Approvati i risultati finanziari di Gruppo al 31 dicembre 2023”. In any case of discrepancy between the English and the Italian versions, the original Italian document is to be given priority of interpretation for legal purposes.

Nexi

Nexi is Europe's PayTech company operating in high-growth, attractive European markets and technologically advanced countries. Listed on Euronext Milan, Nexi has the scale, geographic reach and abilities to drive the transition to a cashless Europe. With its portfolio of innovative products, e-commerce expertise and industry-specific solutions, Nexi provides flexible support for the digital economy and the entire payment ecosystem globally, across a broad range of different payment channels and methods. Nexi’s technological platform and the best-in-class professional skills in the sector enable the company to operate at its best in three market segments: Merchant Solutions, Issuing Solutions and Digital Banking Solutions. Nexi constantly invests in technology and innovation, focusing on two fundamental principles: meeting, together with its partner banks, customer needs and creating new business opportunities for them. Nexi is committed to supporting people and businesses of all sizes, transforming the way people pay and businesses accept payments. It offers companies the most innovative and reliable solutions to better serve their customers and expand. By simplifying payments and enabling people and businesses to build closer relationships and grow together, Nexi promotes progress to benefit everyone. www.nexi.it/en www.nexigroup.com

FY 2023 P&L – Reported vs Normalised

Reported data at current FX with ISP merchant book acquisition in Croatia consolidated from February 28th 2023. Normalised data pro-forma for M&A (i.e. ISP merchant book acquisition in Croatia consolidated from January 1st 2023), at constant FX and excluding non‐recurring items and other one-offs (e.g. D&A of customer contracts).

Income Statement

Balance Sheet

________________________

1 2022 and 2023 pro-forma normalised managerial data at constant FX and scope (i.e. ISP merchant book acquisition in Croatia).
2 Volumes data include sales, International schemes and exclude SIA. For Italy: data also include national schemes for ISP merchant book only. For Nordics and DACH region: data include regular business and exclude non-card based transactions from e-commerce.
3 Managerial figure.
4 Net profit to which non-recurring items and D&A customer contracts are added back net of taxes.
5 Operating cash flow generation after cash interest expenses and other cash items (cash taxes, IFRS 16 and other)
6 Gross of ~100 €M deferred taxes.+27% y/y growth between ~500 €M excess cash in FY23 (net of the previously mentioned deferred taxes) and 394 €M excess cash in FY22.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240306404390/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye